Australia markets open in 7 hours 37 minutes

Xenon Pharmaceuticals Inc. (XENE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
35.18+0.15 (+0.43%)
As of 12:23PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close35.03
Open35.13
Bid35.21 x 1000
Ask35.35 x 1000
Day's range34.97 - 35.54
52-week range31.79 - 43.75
Volume111,850
Avg. volume318,892
Market cap2.257B
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)-2.50
Earnings date06 Nov 2023 - 10 Nov 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est52.64
  • GlobeNewswire

    Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit

    VANCOUVER, British Columbia, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit to be held on September 20, 2023. Company Fireside Chat Presentation Details: Date:Wednesday, September 20, 2023 Time:4:20 pm Eastern Time Webcast:Register here Presenters:Ian Mortimer, President and Chief Executive OfficerSherry Aul

  • GlobeNewswire

    Xenon Pharmaceuticals Announces Upcoming Investor Webinar with Leading Key Opinion Leaders to Discuss XEN1101 and Major Depressive Disorder

    Live broadcast of webinar on Tuesday, September 19 beginning at 11:30 am ETVANCOUVER, British Columbia, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will host an investor webinar with two leading key opinion leaders (KOLs) focused on major depressive disorder. Webinar:“XEN1101 and the Major Depressive Disorder (MDD) Landscape: A Discussion with KOLs”Date:Tuesday, September 19, 2023Time

  • GlobeNewswire

    Xenon Pharmaceuticals Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress

    New interim data from ongoing Phase 2b X-TOLE open-label extension demonstrates improvement in overall quality-of-life (QoL) when compared to baseline Clinically important improvements seen for all patients across important subscales of Seizure Worry, Social Functioning and Medication Effects and for seizure free patients across all QoL subscales Oral presentations showcase Phase 3 clinical trials in focal onset seizures and primary generalized tonic-clonic seizures VANCOUVER, British Columbia,